Physician profile
Michael Schwartz
NPI 1538659107
$3,928.84
in general payments reported to CMS, 2019-2025
25 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $792 · 2023: $878 · 2024: $1,276 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,136.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.93 | 2022-2025 | Mavyret, Rinvoq, Linzess |
| Janssen Scientific Affairs, LLC | $460.28 | 2022-2024 | Stelara |
| Janssen Biotech, INC. | $379.05 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $366.57 | 2022-2025 | Entyvio, Iclusig, Eohilia |
| Gilead Sciences, INC. | $352.20 | 2022-2024 | Vemlidy |
| Medtronic, INC. | $138.63 | 2024 | Barrx |
| Phathom Pharmaceuticals, INC. | $115.17 | 2024 | Voquezna |
| Johnson & Johnson Health Care Systems INC. | $113.63 | 2022 | |
| Intercept Pharmaceuticals, INC. | $113.05 | 2023 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.05 | 2024 | Gilotrif |
| E.R. Squibb & Sons, L.L.C. | $103.82 | 2023 | |
| Pfizer INC. | $90.13 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $62.91 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $52.09 | 2024-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $46.61 | 2024 | Zeposia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $43.94 | 2024 | Exalt Model D |
| Ferring Pharmaceuticals INC. | $43.25 | 2025 | Clenpiq, Rebyota |
| Regeneron Healthcare Solutions, INC. | $38.81 | 2023-2025 | Dupixent |
| Genzyme Corporation | $38.76 | 2022-2025 | |
| Laborie Medical Technologies Corp. | $31.79 | 2025 | |
| Qol Medical, LLC | $23.40 | 2024 | Sucraid |
| Eisai INC. | $16.94 | 2025 | |
| Lilly USA, LLC | $15.75 | 2025 | Omvoh |
| Vivus LLC | $14.14 | 2025 | Pancreaze |
| Mallinckrodt Hospital Products INC. | $13.94 | 2023 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.